Treatment outcomes in confluent and reticulated papillomatosis: A systematic review - 15/02/21
Funding sources: Yuliya Lytvyn was supported by the Canadian Association of Psoriasis Patients Studentship. |
|
Disclosure: Dr Sibbald is the project lead for ECHO Ontario Skin and Wound; is the cochair of Health Quality Ontario Wound Care Guidelines and RNAO Pressure Injury Guideline; and is a speaker, consultant, or investigator for AbbVie, Galderma, Leo, Novartis, PediaPharm, Pfizer, and Valeant. Dr Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GlaxoSmithKline, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Dr Mufti, Authors Sachdeva, Maliyar, and Lansang, and Dr Lytvyn have no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
|
Reprints not available from the authors. |
Vol 84 - N° 3
P. 825-829 - mars 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?